Arca reports Phase IIb data for Gencaro in heart failure patients

Arca biopharma Inc. (NASDAQ:ABIO) reported top-line data from the Phase IIb GENETIC-AF trial in 267 heart failure patients with reduced left ventricular ejection fraction (LVEF) showing that Gencaro bucindolol hydrochloride led to a "similar treatment benefit" on the primary endpoint

Read the full 400 word article

User Sign In